Chen Qingzhong, Zhang Guangbin
Xiamen Eye Center and Eye Institute of Xiamen University, Xiamen, China.
Xiamen Clinical Research Center for Eye Diseases, Xiamen, Fujian, China.
J Ophthalmol. 2024 Oct 15;2024:5571802. doi: 10.1155/2024/5571802. eCollection 2024.
To compare the standard outcomes between the PanOptix and Symfony multifocal intraocular lenses (MIOLs) in Chinese patients. This prospective observational cohort study enrolled patients with cataracts between April 2021 and December 2021 at Xiamen Eye Center Affiliated to Xiamen University. The patients were grouped in the PanOptix (TIOL group) and Symfony (EDF group) according to the IOLs implanted. Uncorrected distant, corrected distance, binocular uncorrected intermediate, and near visual acuity (UNVA), distance-corrected intermediate and near VA (DCNVA) , defocus curve, spectacle independence, contrast sensitivity (CS), and visual disturbances were evaluated after 3 months. Forty patients (80 eyes) were enrolled in the study (20/group). Three months after the operation, UNVA (0.13 ± 0.16) and DCNVA (0.08 ± 0.08) were better in the TIOL group than in the EDF group (0.22 ± 0.08 and 0.22 ± 0.08, respectively, =0.003 and < 0.001, respectively). The TIOL group achieved a better-than-0.15-logMAR VA from +0.5 D to -2.5 D (40 cm). VAs of the TIOL group from -1 D (100 cm) to -4 D (25 cm) were better than in the EDF group ( < 0.05). There were no significant differences in the intermediate and far vision outcomes ( > 0.05). Total near-vision spectacle independence was higher in the TIOL group (80%) than in the EDF group (50%) (=0.039). Compared with EDF, TIOL leads to better near-vision outcomes without significant differences for intermediate and distant vision outcomes. ClinicalTrials.gov identifier: ChiCTR2100044558.
比较中国患者中PanOptix和Symfony多焦点人工晶状体（MIOLs）的标准结局。这项前瞻性观察性队列研究纳入了2021年4月至2021年12月在厦门大学附属厦门眼科中心就诊的白内障患者。根据植入的人工晶状体，将患者分为PanOptix组（TIOL组）和Symfony组（EDF组）。术后3个月评估未矫正远视力、矫正远视力、双眼未矫正中视力和近视力（UNVA）、距离矫正中视力和近视力（DCNVA）、散焦曲线、眼镜独立性、对比敏感度（CS）和视觉干扰。40例患者（80只眼）纳入研究（每组20例）。术后3个月，TIOL组的UNVA（0.13±0.16）和DCNVA（0.08±0.08）优于EDF组（分别为0.22±0.08和0.22±0.08，P分别为0.003和<0.001）。TIOL组在+0.5 D至-2.5 D（40 cm）时达到优于0.15 logMAR的视力。TIOL组从-1 D（100 cm）至-4 D（25 cm）的视力优于EDF组（P<0.05）。中视力和远视力结局无显著差异（P>0.05）。TIOL组的总近视力眼镜独立性（80%）高于EDF组（50%）（P=0.039）。与EDF相比，TIOL可带来更好的近视力结局，而中视力和远视力结局无显著差异。ClinicalTrials.gov标识符：ChiCTR2100044558。
